SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CoTherix (CTRX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (5)3/22/2005 2:55:09 PM
From: rkrw  Read Replies (1) of 18
 
I think you hit on the main concern, is this a viable product? Can ventavis alone carry ctrx?

Your price assumption is way low. I think remodoulin/flolan sell for upwards of $100K per patient. I'm not sure what ventavis is being priced at but I'd assume closer to $50K. Reaching 3000 patients is no given however. uthr has around 1000, I think, after several years.

ctrx looks very cheap but I'm concerned about its viability as a one product company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News